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Mark Berner Hansen1 and Niels Bindslev2
Abstract
Background: Investigations of colorectal carcinogenesis have mainly focused on examining neoplastic tissue. With
our aim of identifying potentially cancer-predisposing molecular compositions, we chose a different approach by
examining endoscopically normal appearing colonic mucosa of patients with and without colorectal neoplasia
(CRN). Directed by this focus, we selected 18 genes that were previously found with altered expression in colorectal
cancer affected mucosa.
Methods: Biopsies of colonic mucosa were sampled from 27 patients referred for colonoscopy on suspicion of
colorectal disease. Of these, 14 patients had present or previous CRN and the remaining 13 patients served as
controls. Using qPCR and Western blot technique, we investigated mRNA and protein expressions. Expressions
were investigated for selected kinases in the extracellular signal-regulated kinase/mitogen activated protein kinase
(ERK/MAPK), the phosphoinositide 3-kinase/Akt, and the Wnt/β-catenin pathways as well as for selected phosphatases
and several entities associated with prostaglandin E2 (PGE2) signaling. Colonic mucosal contents of PGE2 and PGE2
metabolites were determined by use of ELISA.
Results: We found up-regulation of ERK1, ERK2, Akt1, Akt2, PLA2G4A, prostanoid receptor EP3 and phosphatase scaffold
subunit PPP2R1B mRNA expression in normal appearing colonic mucosa of CRN patients compared to controls.
Conclusion: Present study supports that even normal appearing mucosa of CRN patients differs from that of non-CRN
patients at a molecular level. Especially expression of ERK1 mRNA was increased (p = 0.007) in CRN group. ERK1 may
therefore be considered a potential candidate gene as predictive biomarker for developing CRN. Further validation in
larger cohorts are required to determine such predictive use in translational medicine and clinics.
Keywords: Extracellular signal-regulated kinase (ERK), Akt, Prostaglandin E2, β-Catenin, Colorectal cancer
Background
Investigating endoscopically normal appearing mucosa
Most investigations of tumorigenesis focus on alterations
in neoplastic tissues or transformed cells in culture. Due
to progressive derangement in neoplastic tissue of the
genome, growth factor-signaling, and metabolic net-
works, screening of colorectal neoplasia (CRN) tissue
itself demonstrates many alterations. Thus, investigations
on CRN tissues provide limited information regarding
possible predisposing factors and their role in transform-
ing normal appearing mucosa to CRN. Screening of endo-
scopically normal appearing mucosa from patients with
CRN and comparing it to mucosa of non-CRN patients
may generate important new insights into identifying sub-
jects with increased risk of developing CRN (risk stratifi-
cation, predictive biomarker). As such, we and a few
others have communicated altered expression of several
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genes and proteins in normal appearing mucosa from
CRN patients [1–4].
Wnt/β-catenin-, ERK/MAPK- and PI3K/Akt pathways in
colorectal cancer
Among the frequently disrupted signaling pathways, per-
turbation of the Wnt/β-catenin pathway has been identi-
fied in early lesions of colorectal epithelium. Concurrently,
Wnt/β-catenin perturbation is regarded a major initiating
event in development of CRN as its tumor-suppressor
gene adenomatous polyposis coli (APC) is inactivated in
about 80% of sporadic colorectal cancers, CRC. APC in-
activation leads to increased nuclear transfer of β-catenin
with formation of a constitutively active β-catenin-T-cell
factor complex [5]. In addition to perturbation of Wnt/β-
catenin pathway, two other major pathways, the extracel-
lular signal-regulated kinase/mitogen activated protein
kinase (ERK/MAPK) and phosphoinositide 3-kinase/Akt
(PI3K/Akt)-signaling pathways, are frequently overactive
in CRC. Activation of these pathways stimulate cell
growth, proliferation and survival [6, 7]. As such, con-
stitutive activation of the ERK/MAPK pathway occurs
via mutations in KRAS in about 50% of CRCs [8].
Less frequently, dysregulation of PI3K/Akt pathway is
observed following mutations in the CA subtype of
the phosphoinositide-3-kinase gene (PIK3CA) or in
the PI3K/Akt-related phosphatase and tensin homolog
(PTEN) [9, 10].
Prostaglandin E2 in colorectal carcinogenesis
During carcinogenesis the regulatory system of cell cycle
is affected by both internal genetic alterations and exter-
nal signaling. In particular, cytokines, growth factors and
eicosanoids trigger signal transduction cascades through
receptor tyrosine kinases and G protein-coupled recep-
tors e.g., epidermal growth factor via its receptor EGF
and PGE2 through prostanoid receptors type 1–4.
Among the prostanoids, prostaglandin E2 (PGE2) has
been identified as the principal entity promoting cell
growth and survival in CRN. It is believed that PGE2
execute these effects via the PI3K/Akt-, ERK/MAPK-
and Wnt/β-catenin pathways [11]. Induction of PGE2
signaling is also well-established as an early and critical
step in development of CRN and in tumor progression
[12, 13]. All these pathways and PGE2 metabolism are
schematized in Fig. 1.
Hypothesis and aim of study
We hypothesized that up-regulation of some specific
CRC-associated kinases and PGE2-related proteins occur
in normal appearing colonic mucosa. The aim of this
study was to test this 0-hypothesis by screening colonic
mucosa for a panel of 18 specific genes, all proven
altered and involved in CRC development. Tissue
samples were endoscopic biopsies obtained from pa-
tients with and without CRN. Indeed, identifying per-
turbation of some of these signaling networks might give
further insight into colorectal carcinogenesis per se and
also identify potential predictive biomarkers.
Materials and methods
Study population
Patients ≥ 50 years of age, referred for colonoscopy on
suspicion for colorectal disease, were screened for en-
rollment in the study. Patients with a history of CRN, or
CRN detected during colonoscopy, were included in
CRN group. Patients with no present or history of CRN
represents the control group. Patients were excluded if
they received weekly medications in the form of nonste-
roidal anti-inflammatory drugs, paracetamol, systemic
corticosteroids and/or cytostatics. Furthermore, incom-
plete colonoscopy, inflammatory bowel disease, malab-
sorption or previous sigmoid resection and exposure to
radiation or chemotherapy within the last year precluded
enrollment. Finally, patients were also excluded if
diagnosed with any of the genetic CRN syndromes (e.g.
adenomatous polyposis coli and hereditary nonpolyposis
colorectal cancer), as the focus of this study was spor-
adic CRN. Risk stratification of adenomas was per-
formed based on number, size and histology grade in
accordance with the European guidelines for quality as-
surance in CRC screening and diagnosis [14].
Biopsy procedure
Six biopsies from each patient were obtained during en-
doscopy from endoscopically normal appearing mucosa
using standard biopsy forceps (Boston Scientific, Radial
Jaw 4, outside diameter of 2.2 mm). Biopsies were ob-
tained approximately 30 cm orally from the anal verge
on retraction of the endoscope and at least 10 cm from
endoscopically abnormal appearing mucosa.
Statistical analysis
Values were expressed as the mean ± SEM and as fold
change. Data was analyzed using two-tailed unpaired t-test.
A p-value less than 0.05 was considered statistically signifi-
cant. Bonferroni correction was applied. Calculations were
performed using Microsoft Excel 2007 and GraphPad
Prism 6.01.
qPCR
Two biopsies, obtained from each patient, were stored in
RNAlater (Thermo Fisher Scientific, Wilmington, DE,
USA) at − 80 °C. Biopsies were homogenized using a
TissueLyser II (Qiagen, Copenhagen, Denmark), and RNA
was extracted using RNeasy Mini Kit (Qiagen, Copenhagen,
Denmark). RNA concentration and purity were determined
using a NanoDrop® 2000 (Thermo Fisher Scientific,
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Wilmington, DE, USA), the latter by A260/A280 and A260/
A230 absorbance ratios. RNA was converted to cDNA using
the iScript™ cDNA Synthesis Kit (BioRad, Copenhagen,
Denmark) according to the manufacturers protocol.
Primers against genes of interest were designed, synthesized
and quality controlled by Primerdesign Ltd. (Primerdesign
Ltd., Chandler’s Ford, UK). Primers against β-actin were
designed and synthesized by Section of Endocrinology
Research, Department of Biomedical Sciences, University of
Copenhagen, primerbank reference 4501885a1. Primer se-
quences are listed in Table 1. cDNA was amplified on a
7900HT Fast Real-Time PCR System (Applied Biosystems,
Foster City, CA, USA) using Fast SYBR® Green Master Mix
(Applied Biosystems) in accordance with the manufacturers
protocol. All samples were run in triplicate with β-actin
primers on all plates. Results were analyzed using SDS 2.4
(Applied Biosystems), and expression was calculated by the
2-ΔCt method.
Fig. 1 Simplified schematic illustration of pathways for Wnt/β-catenin, ERK/MAPK and PI3K/Akt and PGE2-metabolism. A) Canonical Wnt/β-catenin
signaling. The engagement of the Wnt receptor, Frizzled, leads to the inhibition of the β-catenin destruction complex, composed of APC, axin
and GSK3β. β-catenin thereby avoids ubiquitination and subsequent degradation, thus allowing it to translocate to the nucleus to activate an
array of regulatory genes. B) The RAS/RAF/MEK/ERK MAPK pathway. Stimulation of the receptor tyrosine kinase (RTK) or G-protein coupled
receptors (GPCRs) leads to sequential activation of RAS, RAF, MEK, and ERK causing modification of substrates promoting cell survival and
proliferation. C) In the PI3K/Akt pathway, activation of the RTK or GPCRs leads to sequential modification of phosphatidyl inositol residues of the
phospholipid bilayer. In this process, PI3K generates PIP3. PIP3 in association with PDK1 activates Akt. Akt then modulates the activity of
downstream substrates including mTOR, thus promoting proliferation and cell survival. D) PGE2-metabolism. PGE2-synthesis begins with catalytic
hydrolysis of membrane phospholipids by cytoplasmic phospholipase A2 (cPLA2), thus releasing arachidonic acid (AA). By the action of the COX-1
and COX-2, AA is converted to prostaglandin H2 (PGH2). PGH2 is then converted to PGE2 by prostaglandin E synthase (PTGES). The main exporter
of PGE2 is thought to be multi-drug resistance related polypeptide 4 (MRP4). Removal of PGE2 from the extracellular compartment around target
cells occurs by diffusion to the blood stream and subsequent uptake and degradation in lung, liver or kidney endothelial cells or by import to
colonic epithelial cells through the prostaglandin transporter (PGT) and subsequent degradation by 15-prostaglandin dehydrogenase (15-PGDH).
Through autocrine and paracrine signaling, extracellular PGE2 stimulates the prostaglandin receptors EP1–4. The EPs are GPCRs with EP1 being
Gαq-coupled while EP2 and EP4 are Gαs-coupled. EP3 is capable of coupling with different G-proteins including Gαi, Gαs and Gαq
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Western blot and immunohistochemistry
Primary antibodies for Western blots and
immunohistochemistry
The following antibodies were employed to detect target
antigens by Western blot and immunohistochemistry
(IHC), in parenthesis (antibody designator, dilution):
goat anti-COX-1 (C-20, 1:800), mouse anti-β -catenin
(E-5, 1:200) and mouse anti-PGDH (H-3, 1:250) were all
purchased from Santa Cruz Biotechnology, Heidelberg,
Germany. Rabbit anti-ERK1/2 (9102S, 1:1000), rabbit
anti-pERK1/2 (9101S, 11,000) and rabbit anti-panAkt
(C67E7, 1:1500) were all from Cell Signaling, Leiden,
The Netherlands. Rabbit anti-COX-2 (SP21, 1:500) was
from Spring Biosciences, Pleasanton, CA, USA. We did
not succeed in detecting EP3, neither in Western blots
nor in IHC staining, despite using four different anti-
bodies. The following antibodies were tested: Mouse anti-
EP3 antibody (5F5), sc-57,105 (Santa Cruz Biotechnology),
Rabbit anti-EP3 antibody, 101,760 (Cayman Chemicals,
Ann Arbor, MI, USA), Rabbit anti-EP3 antibody, APR-065
(Alomone Labs, Jerusalem, Israel), Rabbit anti-EP3 anti-
body (PTGER3), NBP1–84835 (Bio-techne, Abingdon,
United Kingdom). In addition, attempts to detect cyto-
plasmic phospholipase A2 alpha (cPLA2A) using two
different antibodies (Santa Cruz Biotechnology, sc-454
and Cell Signaling 2832) and protein phosphatase 2
isoform beta of scaffold subunit A (PPP2R1B) using
mouse anti-PPP2R1B (Santa Cruz Biotechnology, sc-13,
600) proved unsuccessful in both Western blots and IHC.
IHC staining for PGT and for COX-2 with two different
antibodies (Cayman Chemicals, 160,126 and Spring Biosci-
ences SP21) was attempted, but was unsuccessful.
Homogenization and solubilization of colonic biopsies for
Western blot analysis
Snap-frozen biopsies were homogenized for 20 s at 5000
rpm in 150 μl buffer (50 mM TrisHCl, pH 8.5, 5 mM
EDTA, 150 mM NaCl, 10 mM KCl, 1% Triton X-100,
5 mM NaF, 5 mM β-glycerophosphate, 1 mM sodium-
orthovanadate and Complete Protease Inhibitor Cocktail
Tablet (Roche, Hvidovre, Denmark)) using a PreCellys 24
(Bertin Instruments, Montigny-le-Bretonneux, France)
and ceramic beads (mix of 1.4 mm and 2.8mm beads,
VWR, Soeborg, Denmark). Solubilization was continued
for 2 h in the same buffer at 4 °C with rotation. The solu-
bilized samples were spun for 15min at 15000 g and the
resulting supernatant collected for further protein deter-
mination and Western blot analysis.
Western blotting
Twenty-four biopsies were analyzed by Western blotting
(12 CRN, 12 controls). 12.5 μg protein was separated on
Table 1 Quantitative real-time PCR primer sequences
Target Forward 5’→ 3’ Reverse 5’→ 3’
β-actin CATGTACGTTGCTATCCAGGC CTCCTTAATGTCACGCACGAT
PLA2G4A GAAAAGTGGGCTAAAATGAACAAG GGGCAATCTTTCTCCATATCAG
COX1 CGTGTGTGTGACCTGCTGAA GTACTCCTCGATGACAATCTTGATG
COX2 CAGGCTTCCATTGACCAGAG TTTCTCCTGTAAGTTCTTCAAATGAT
PTGES GTGGCTATACCTGGGGACTT AATCCAAGGGGCTAAGAAACAT
EP1 ATCTGCTGGAGCCCAATGC GATCTGGTTCCAGGAGGCAA
EP2 CAGACCCTGGTGGCACTG CGAAGAGCATGAGCATCGTG
EP3 TCAATCAGACATCAGTTGAGCAC TTTCTTAACAGCAGGTAAACCCAA
EP4 AGTTTGGAGCGAGAAGTCAGTA GCGGCAGAAGAGGCATTTG
15-PGDH AGTAGTGAACATCAATGAACATCTGA ACTGGGCAAACCGACATCAT
PGT GCCACAGCAGATGAAGCAAG CCACCAGGACGAAGAGTGAG
ERK1 AGAGATCATGCTGAACTCCAAG GTGCTTGCCAGGGAAGATG
ERK2 TGGATGTGGTGTTATGGAAAGA AAGCAGAGACGCAGAATGAC
AKT1 GGCACCCCTTCCTCACAG GGCGTACTCCATGACAAAGC
AKT2 CTGCGGAAGGAAGTCATCATT GGTCGTGGGTCTGGAAGG
β-catenin CCATTACAACTCTCCACAACCT GAGCAAGGCAACCATTTTCTG
GSK3B AAGTAATCCACCTCTGGCTACC AGAAGCAGCATTATTGGTCTGTC
PPP2R1B GGTTCACCTCTCGCACATCT TCTGAGCACAAGGAACGGAAT
PTPRM ACTCGTTGCCACAGTTATAATCTC GTGTATGGTGACAGGTTAGTGATC
Left column: Names of all qPCR-analysed targets. Middle column: Forward primer sequences written 5′→ 3′. Right column: reverse primer sequences
written 5′→ 3′.
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4–20% gradient mini-PROTEAN® TGX™ Gels (Bio-Rad
Laboratories, Copenhagen, Denmark) using the Bio-Rad
Laboratories minigel system. Proteins were transferred
onto an Immobilon-FL Transfer Membrane 45 μM
(Merck Millipore, Hellerup, Denmark) in 25mM Tris
base, 200 mM glycine, 20% methanol, 1% SDS using the
same system. After transfer, membranes were stained
with REVERT™ Total Protein Stain (LI-COR Biosciences,
Cambridge, United Kingdom) and the staining captured
using the Odyssey CLx Imaging System (LI-COR Biosci-
ences) to adjust for protein loading (internal loading
control). Membranes were subsequently blocked for 1 h at
room temperature in blocking buffer (Odyssey Blocking
Buffer (PBS), LI-COR Biosciences). Primary antibody was
applied overnight at 4 °C in blocking buffer. IRDye® 800CW
Secondary Antibodies (1:10000 dilution in blocking buffer,
LI-COR Biosciences) were then applied for 30min at room
temperature and bound antibody detected with the
Odyssey CLx Imaging System (LI-COR Biosciences).
Western blot was repeated twice on the same samples to
ensure reproducibility. Signals originating from target
proteins were quantified in Image Studio Version 3.1 using
REVERT™ Total Protein Stain as internal loading control.
The target protein signal in each lane was normalized to
the total protein stain in the corresponding lane. The nor-
malized mean target protein signal originating from the
control group was then set to 1 and all values expressed
relative to this value.
Immunohistochemistry
Biopsies were fixed immediately in 4% formaldehyde and
kept in the formaldehyde solution at 4 °C until cutting.
Cryoprotection was performed by two successive overnight
incubations at 4 °C in PBS containing first 20% sucrose and
subsequently 30% sucrose. After cryoprotection, 10–15 μm
cryostat sections were cut. For staining, sections were sub-
jected to antigen retrieval by boiling in 10mM citric acid
pH 6.0 for 5–10min. After washing in PBS, unspecific
binding was blocked for 30min in PBS containing 0.1% tri-
ton X-100 and 0.2% fish skin gelatine. Primary antibodies
were diluted in the same buffer and incubated overnight at
4 °C. Bound primary antibody was detected by incubation
in AlexaFluor®-conjugated secondary antibodies (Thermo
Fisher Scientific, Roskilde, Denmark) for 1 h at room
temperature. Nuclei were detected using 4′,6-diamidino-
2-phenylindole (DAPI, Thermo Fisher). Sections were
mounted in Prolong Diamond (Thermo Fisher Scientific).
IHC staining for cytoplasmic phospholipase A2 alpha
(cPLA2A), cyclooxygenase 1 and 2 (COX-1, COX-2), pros-
taglandin transporter (PGT), 15-hydroxyprostaglandin
dehydrogenase (15-PGDH), EP3, β-catenin, ERK1/2, AKT
and protein phosphatase 2 isoform beta of scaffold subunit
A (PPP2R1B) was attempted. Only COX-1, 15-PGDH and
β-catenin were reliably detected.
Confocal microscopy
Confocal images were captured using a Zeiss LSM 710
confocal microscope. Images were captured using either
a × 20 objective (NA 0.8) or a × 63 oil immersion object-
ive (NA 1.4). Pinhole size was set to 1, the pixel format
was 1024 × 1024 and line averaging was employed to re-
duce noise.
Determination of mucosal contents of PGE2 and
prostaglandin E metabolites
Immediately upon extraction, biopsies were placed in 1
ml of Tris-buffered Ringer’s solution (pH 7.4) and snap
frozen in liquid nitrogen. The Ringer’s solution was
composed of (in mM) 20 Tris, 130 NaCl, 1 CaCl2, 2.5
K2HPO2 and 1 MgSO4 as well as protease inhibitor
cocktail powder (one bottle dissolved in 100ml Ringer’s
solution), from Sigma-Aldrich (Schnelldorf, Germany,
cat. no. P2714). In order to inhibit both synthesis and
catabolism of PGE2, the Ringer’s solution additionally
contained 13 μM of indomethacin from Sigma-Aldrich
(Seelze, Germany) and 110 μM of the 15-PGDH-inhibitor
5-[[4-(ethoxycarbonyl)phenyl]azo]-2-hydroxy-benzeneace-
tic acid (Santa Cruz Biotechnology, Heidelberg, Germany,
cat. no. 78028–01-0). 110 μM 15-PGDH inhibitor concen-
tration was obtained by diluting a solution of 1 mg inhibi-
tor dissolved in 33 μl DMSO to a ratio of 1 DMSO:833
Ringer. Samples were stored at − 80 °C. After a quick
thaw, biopsies were retrieved and dabbed twice on Wat-
man filter no 1 and weighed (range 5–15mg) and sus-
pended in 1ml Ringer. Samples were then systematically
pestel-squeezed to promote breakage of cell membranes
and centrifuged for 30 s at 10,000 rpm in a Beckman
microfuge to form a supernatant. Volumes of 50 μL super-
natant were used for measuring PGE2 as well as the stable
PGE2 metabolite PGE-M according to manufacturer’s in-
structions using ELISA kits from Cayman Chemical, Ann
Arbor, MI, USA, cat. No. 514010 and 514,531. The ELISA
results were adjusted for the weight of sample biopsy. Test
for possible interference from the organic solvent DMSO
was performed with up to double the maximal Ringer-
added concentration of DMSO and demonstrated no shifts
in the standard curves. Tests for general interference due to
different dilutions of samples were performed and proved
no need for adjustments.
Results
Patient characteristics
Twenty-seven patients were included. Fourteen patients
in CRN group and 13 patients in control group. One
additional patient was excluded from analysis due to his-
tologically verified hyperplastic polyps, which are not
classified as neoplasia. Median age was 64 years in CRN
group and 62 years in control group. CRN group con-
tained 7 (7/14) women versus 8 (8/13) in control group.
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Nine patients (9/14) had present CRN, while the 5 (5/14)
remaining patients had previously been diagnosed with
CRN. Three patients (3/14) had primary CRC. The
remaining 11 (11/14) patients had tubular adenomas
which were risk stratified as being high risk adenomas
(n = 3/14), intermediate risk adenomas (n = 3/14) and low
risk adenomas (n = 5/14) based on number, size and hist-
ology grade in accordance with the European guidelines
for quality assurance in CRC screening and diagnosis [14].
Eight patients (8/14) from CRN group and 6 (6/13)
patients from control group had one or more comor-
bidities such as anemia, diabetes, hypothyroidism,
cardiovascular disease, asthma, osteoporosis, psoriasis,
chronic dermatitis, allergic rhinitis and/or a psychi-
atric diagnosis. Two patients in CRN group had a his-
tory of primary prostate cancer without metastasis. In
the control group 4 patients had a history of primary
non-colorectal cancer without metastasis: Melanoma
(n = 1/14), testis seminoma (n = 1/14), uterus cancer
(n = 1/14) and breast cancer (n = 1/14). Nine patients
(9/14) in CRN group and 10 (10/13) patients in control
group received medications e.g. anti-thrombotics,
angiotensin-converting-enzyme inhibitors, angiotensin-II-
receptor antagonists, β-blockers, calcium-blockers, statins,
diuretics, β2-agonists, anti-histamines, insulin, levothyrox-
ine, proton pump inhibitors, laxantia, loperamid, anti-
depressants, estrogen or bisphosphonates. There were no
apparent differences between the CRN and control groups
in use of medications nor in co-morbidity profiles. Level
changes for ERK, Akt, β-catenin and PPP2R1B expression.
We screened colonic mucosa for a panel of 18 specific
genes, all proven altered and involved in CRC develop-
ment. All 18 targeted mRNAs were detected. Perturbed
expression profile was observed in CRN patients with
significantly higher mRNA-expressions measured for the
following gene transcripts: PLA2G4A, EP3, ERK1, ERK2,
Akt1, Akt2 and PPP2R1B, Table 2 and Fig. 2.
For the CRN group we detected upregulation of ERK1
(p = 0.007) and ERK2 (p = 0.02) which are ubiquitous regu-
lators of cellular proliferation, differentiation, survival and
transformation. ERK1 and ERK2 were expressed 1.87 and
2.0 times higher, respectively, in CRN patients. ERK1 expres-
sion was higher compared to ERK2 in both patient groups.
Akt1 and Akt2 were both significantly up-regulated in CRN
group (p = 0.02 and p = 0.041, respectively). β-catenin was
highly expressed in both groups and with substantial vari-
ability in CRN group. The phosphatase subunit PPP2R1B,
which is considered a negative regulator of both ERK and
Akt activation and a stimulator of Wnt/β-catenin signaling,
was significantly up-regulated in CRN group (p = 0.03).
Level changes for PLA2G4A and EP3
Analysis of entities in PGE2 metabolism by qPCR
demonstrated expression of PLA2G4A, which encodes a
major enzyme involved in arachidonic acid mobilization,
was significantly increased in CRN group (p = 0.02).
With respect to the EP-receptors, EP4 had by far the
highest expression, followed by EP2 and EP3, while EP1
showed the lowest expression. Only EP3 was signifi-
cantly up-regulated in CRN group compared to controls
(p = 0.016). Of all investigated mRNAs, 15-PGDH (the
major enzyme involved in PGE2 degradation), showed
the highest expression in both groups and 1.9-fold
higher expression in CRN group compared to controls
(p = 0.066). Expression of COX-1 was higher than COX-2
in both groups (CRN 2.4-fold; controls 2.5-fold), while
none of the two COX enzymes were significantly altered
between patient groups. When Bonferroni correction was
applied none of the 18 investigated genes reached the re-
quired significance level of p < 0.0028.
Trend towards increase in β-catenin, COX-1, COX-2 and
ERK1 protein expression
To determine whether the changed mRNA expression pro-
file observed in CRN patients was associated with changes
in the protein expression level of these targets, we next per-
formed Western blot analysis on colonic biopsies from CRN
patients and controls. We successfully detected COX-1,
COX-2, 15-PGDH, ERK1/2 and the active phosphorylated
ERK1/2 (pERK1/2) proteins as well as AKT (using an anti-
body that detects AKT1–3) and β-catenin. We analyzed
the protein expression level for each of these targets in the
control group (12 biopsies) and compared them to the ex-
pression levels in the CRN group (12 biopsies). Relative
protein expressions for the detected target proteins are
shown in Fig. 3. The Western blot results suggest a trend
towards a moderate increase in β-catenin as well as minor
increases in COX-1, COX-2 and ERK1. The observed
changes were not, however, statistically significant.
Localization of COX-1, 15-PGDH and β-catenin
We next sought to investigate the localization of target
proteins by immunohistochemistry. We attempted to
detect cPLA2A, COX-1, COX-2, EP3, PGT, 15-PGDH,
ERK1/2, AKT, β-catenin and PPP2R1B in colonic
biopsies from CRN patients and controls. The targets
were selected to map localizations of proteins involved
in different aspects of the PGE2 pathway and to study
any differences in protein localizations and/or possible
expressions in CRN patients compared to controls.
Possibly due to inadequate (human) specificity of the
tested antibodies or paucity of target proteins, we failed
to reliably detect cPLA2A, COX-2, PGT, EP3, ERK1/2,
AKT and PPP2R1B in IHC. Only COX-1, 15-PGDH and
β-catenin were detected. The results are shown in Fig. 4.
15-PGDH displayed strong cytoplasmic staining in epi-
thelial cells at the crypt apex. COX-1 was selectively
expressed in a small subset of cells in the epithelial cell
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layer where the enzyme displayed a reticular, intracellu-
lar localization associated with the perinuclear area. We
believe that these COX-1 expressing cells represent
epithelial tuft cells [15, 16]. β-catenin showed expression
throughout the epithelial layer and was mainly associated
with lateral membranes of the epithelial cells. No apparent
differences in protein localization were observed between
CRN and control groups.
Indication of increased prostaglandin E2 content in
mucosa of CRN patients
Mean mucosal PGE2 content (pg/mg tissue) was 1234 (± 98)
in CRN group and 980 (± 109) in control group, p = 0.095,
Fig. 5. Translated to tissue concentrations, the values come
to 3.50 μM in CRN and 2.78 μM in control group. Mean
mucosal PGE2 metabolite content (pg/mg tissue) was 12.58
(± 2.54) in CRN group versus 10.90 (± 2.05) in control group.
Fig. 2 Fold change in mRNA expressions in normal appearing colonic mucosa from CRN patients compared to controls. CRN group: N = 14, Control
group: N = 13. Data are expressed as fold change of mRNA expression in CRN group compared to control group
Table 2 Difference in mRNA expression in CRN versus controls
Control mean (±SEM) CRN mean (±SEM) Fold change P
PLA2G4A 0.0063 (± 0.0008) 0.0110 (± 0.0017) 1.75 0.020*
COX-1 0.0054 (± 0.0007) 0.0069 (± 0.0009) 1.26 0.252
COX-2 0.0022 (± 0.0006) 0.0029 (± 0.0007) 1.31 0.490
PTGES 0.0008 (± 0.0001) 0.0010 (± 0.0002) 1.26 0.388
EP1 0.000029 (± 0.0000079) 0.000034 (± 0.0000064) 1.18 0.626
EP2 0.0013 (± 0.0002) 0.0018 (± 0.0003) 1.33 0.207
EP3 0.0011 (± 0.0002) 0.0026 (± 0.0005) 2.34 0.016*
EP4 0.0217 (± 0.0021) 0.0305 (± 0.0047) 1.41 0.096
PGT 0.0301 (± 0.0032) 0.0364 (± 0.0038) 1.21 0.217
15-PGDH 0.2283 (± 0.0572) 0.4350 (± 0.0921) 1.91 0.066
ERK1 0.0640 (± 0.0076) 0.1198 (± 0.0171) 1.87 0.007**
ERK2 0.0018 (± 0.0002) 0.0036 (± 0.0007) 2.00 0.020*
Akt1 0.0311 (± 0.0033) 0.0564 (± 0.0092) 1.82 0.020*
Akt2 0.0193 (± 0.0020) 0.0283 (± 0.0035) 1.46 0.041*
β-Catenin 0.1694 (± 0.0197) 0.2662 (± 0.0486) 1.57 0.082
GSK3β 0.0289 (± 0.0031) 0.0759 (± 0.0220) 2.63 0.054
PPP2R1B 0.0196 (± 0.0022) 0.0317 (± 0.0048) 1.62 0.030*
PTPRM 0.0079 (± 0.0011) 0.0142 (± 0.0029) 1.81 0.059
Control group: N = 13, CRN group: N = 14. Data are expressed as the mean (±SEM) and as fold change of mRNA expression in CRN group compared to control
group. * = p < 0.05, ** = p < 0.01
Petersen et al. BMC Cancer          (2019) 19:643 Page 7 of 13
Discussion
Normal appearing, tumor-remote colonic mucosa in
CRN patients has so far been scarcely explored. Here we
document significant up-regulation of mRNA expression
for the ERK1, ERK2, Akt1, Akt2, PLA2G4A, the prosta-
noid receptor EP3 as well as for PPP2R1B in normal
appearing colonic mucosa from patients with CRN,
Table 2. The range in fold change of these gene expres-
sions was 1.46–2.34. The fact that our observed changes
in gene expression were somewhat modest compared to
changes reported in cancer tissues was to be expected
since we examined normal appearing colon mucosa dis-
tant from neoplastic tissue. Furthermore, CRN group
encompassed a wide range of stages of CRN and both
patients with current CRN as wells as patients with a
history of CRN. Since we perceive CRN development as
a spectrum from low-grade adenomas to CRC, all CRN
data were pooled into one group, tacitly acknowledging
that different stages of CRN are likely to contribute dif-
ferentially to the observed alterations of gene expression.
Thus, it was a heterogenous CRN group with a limited
number of observations and hence the observed changes
between groups were not strong enough to reach the
required significance level of a Bonferroni correction.
However, our results point towards perturbed gene ex-
pression in the normal colon mucosa of CRN patients.
These alterations in mRNA expression did not translate
into significant alterations at protein level, Fig. 3. Al-
though, the mRNA expressions of the above stated gene
transcripts have previously been shown perturbed in
CRC affected mucosa, we do not know the precise bio-
logical impact of the altered gene expressions in the nor-
mal appearing mucosa.
ERK and Akt signaling pathways
We observed significant up-regulation of mRNA expres-
sion for ERK1, ERK2, Akt1 and Akt2 in normal appear-
ing mucosa of CRN patients. Contrary, examining
protein abundance, we found a marginal increase of
ERK1 (p = 0.09) in CRN-group, while phospho-ERK1,
ERK2 and panAkt were similar between groups. One
might argue that protein expression, especially for phos-
phorylated proteins, is a more direct marker for cell
function compared to mRNA. However, Western blot
measurements of protein expression are far less accurate
than the qPCR method for measuring mRNA. The ob-
served up-regulation of both ERK and Akt mRNAs are
quite interesting findings given the fact that ERK/MAPK
and PI3K/Akt pathways are well established important
pathways in regulating proliferation and human carcin-
oma survival [17, 18]. ERK1 and ERK2 are ubiquitous
regulators of multiple cellular processes and dysregu-
lated nuclear accumulation of activated ERKs (pERK)
can lead to genomic instability and subsequent CRN
progression [19–23]. It is difficult to assign a precise role
of ERK signaling in human carcinogenesis due to its
complexity and dependence on signaling intensity. Still,
ERKs may play oncogenic and/or tumor suppressing
Fig. 3 Protein expression. a Representative Western blot images for seven different targets, indicated to the right of bands. CTRL: samples
originate from control group, CRN: samples originate from neoplasia group. b Quantification of band intensities for nine different target proteins.
REVERT™ Total Protein Stain was used as internal loading control (please see materials and methods section). The expression level of each target
protein was normalized to the mean expression level in the control group which was set to 1. Data are expressed as the mean ± SEM
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Fig. 4 Immunohistochemical analysis of 15-PGDH, COX-1 and β-catenin. Representative confocal images demonstrating the cellular and
subcellular localization of 15-PGDH (a) and COX-1 (b) and β-catenin (c) in human colonic biopsies. Staining for Na-K-ATPase and DAPI was
included to locate the plasma membrane and nuclei, respectively. To the left: CTRL; Control group. To the right: CRN; colorectal neoplasia group
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roles in normal appearing colonic mucosa [24–26]. Our
findings of markedly lifted expression levels for ERK1
points to this kinase as a possible useful predictive bio-
marker for CRN development. In addition to ERK and
Akt, we found enhanced mRNA expression of the struc-
tural subunit Aβ, PPP2R1B, which is an isoform of the
scaffold subunit of protein phosphatase 2A (PP2A).
PP2A is considered a tumor suppressor and a negative
regulator of both ERK and Akt activation and stimulator
of Wnt/β-catenin signaling [27, 28]. In the present study,
PPP2R1B mRNA was up-regulated in CRN group and
we speculate that this is a compensatory up-regulation
to counteract up-regulation of Akt and ERK.
Prostaglandin E2 signaling
Prostaglandin E2 synthesis and mucosal content
As mentioned PLA2G4A mRNA expression is up-
regulated in normal appearing colonic mucosa from
CRN patients, Table 2. The PLA2G4A gene encodes the
enzyme cPLA2A which is a key enzyme involved in ara-
chidonic acid mobilization and upstream release of many
lipid mediators including lysophospholipids, prostaglan-
dins, leukotrienes and lipoxins [29, 30]. Understanding
how the cPLA2A enzyme regulates tumorigenesis is
hampered by the entwined effects of its many interacting
products of downstream eicosanoid mediators. Mean-
while, our result of up-regulated PLA2G4A could indi-
cate an increased substrate concentration for eicosanoid
generation. Thus, despite we did not observe up-
regulation of COX-1 and -2 enzyme mRNA, a higher
substrate level may yield a higher PGE2-concentration.
This corroborates with previous reports demonstrating
higher sensitivity to indomethacin in CRN patients
versus controls [3, 16, 31]. In terms of the resulting mu-
cosal content of active PGE2, our assay indicates that the
mean concentration is lifted (26%) in CRN patients. The
observed mucosal PGE2 content in this study may be
transformed into tissue concentrations of 3.50 and
2.78 μM for CRN and control patients, respectively.
Based on these findings and our finding of a high-
affinity EP4 subtype receptor (estimated EC50 of 10 nM)
in similar patient mucosal tissue samples (S. Kjaergaard
et al., unpublished; U.R. Feddersen et al., unpublished),
we assume that the majority of PGE2 is to be found
intracellularly and that the extracellular mucosal concen-
trations are 3 orders of magnitude lower. Taken together,
findings suggest presence of a mild chronic inflamma-
tion in endoscopically normal appearing mucosa of CRN
patients. A similar 27% marginal increase (p = 0.09) in
mean colonic mucosal PGE2 concentration was reported
by Krishnan et al. for patients treated for CRN [32].
Prostaglandin E2 receptors
Investigating EP receptors, we found EP3 to be up-
regulated in CRN patients, Table 2. Interestingly, a study
of paired colonic normal and tumor tissues from CRN
patients, reported the tumor tissue had downregulated
expression of EP3 mRNA [33]. Of note, the EP3 receptor
is unique among EP receptor subtypes, in that there are
multiple isoforms generated through alternative mRNA
splicing in the carboxyl tail of the EP3 gene resulting in
isoform specific differences in G-protein coupling and
signaling [34]. Our EP3 qPCR-primer did not differenti-
ate between EP3 isoforms. Nonetheless, the major EP3
isoform is thought to couple to an inhibitory G protein
(Gi), and hence the major outcome of PGE2-EP3
Fig. 5 Mucosal prostaglandin E2 contents. On the left: Mucosal prostaglandin E2 concentrations. On the right: Mucosal concentration of prostaglandin
E metabolites. Each mark represents one study patient. White squares = CTRL, control group (N = 14), Black dots = CRN group (N = 14)
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receptor signaling is inhibition of adenylate cyclase and
activation of the ERK/MAPK pathway [35]. Thus, the
role of the EP3 receptor in tumorigenesis seems to be
multifaceted and isoform-dependent. As for cPLA2A,
azoxymethane-induced colon cancer development is en-
hanced in EP3 receptor knockout mice, suggesting an
antitumorigenic function for the EP3 receptor [33, 36].
Further studies of the mRNA and protein expressions of
individual EP3 isoforms in normal appearing colonic
mucosa from humans are warranted.
Prostaglandin E2 influx and degradation
In terms of cellular PGE2 influx and subsequent elimin-
ation we found no change in mRNA expressions of the
major and specific PGE2 influx transporter PGT in CRN
patients. The expression of PGT, an organic anion poly-
peptide transporter (OATP) has been reported downreg-
ulated in CRC tissue [37]. However, other specific PGE2
OATP-transporters, potentially involved in regulatory
removal of PGE2, were not investigated in the present
study. However, our group reported compensatory
increase in the level of two OATP PGE2 influx trans-
porters, OATP2B1 and OATP4A1, located in the baso-
lateral membrane of human colonic epithelia from CRN
patients [38]. Since lowered expression of the PGE2
inactivating enzyme, 15-PGDH, has been observed in can-
cer cells [39], we hypothesized a decrease in 15-PGDH
expression in CRN patients compared to controls.
Meanwhile, this hypothesis was not supported by a nearly
2-fold (p = 0.066) increase in 15-PGDH mRNA expression
in CRN patients. The mechanism(s) for the observed
elevation of 15-PGDH mRNA expression in the normal
appearing colonic mucosa of CRN patients is unresolved.
We speculate that a negative feedback balance between
increased PGE2 production and subsequent increase in
removal/inactivation is present in the normal appearing
mucosa of CRN patients.
Is our finding of perturbed mRNA expression a CRN
predisposition?
Our suggestions of perturbed mRNA expressions as pos-
sible predisposing factors for the individual development
of CRN could also be explained by the extant tumor
tissue per se. Thus, at play could be local paracrine
inducers or more systemic neuro-, endo- or immuno-
crine signaling from tumor to neighboring colonic mu-
cosal areas. Yet, another pathway might be special
cancer-inducing environmental stimulants as products
of food digestion or microbial activity affecting gene ex-
pression in non-tumor mucosa. A conclusive settlement
of this question between inborn predisposing constitu-
tions versus tumor activity or environmental factors in
normal appearing epithelium will require larger popula-
tion studies. Regardless of the underlying mechanisms,
our observation of up-regulation of several genes in nor-
mal appearing colonic mucosa suggests that normal
appearing mucosa of CRN patients differs from non-
CRN patients at a molecular level. Since up-regulated
genes in this study have been found perturbed in CRC
studies on colonic biopsies of affected mucosa, they
could indicate possible predispositions for CRC develop-
ment. The exploratory nature of our relatively small
study cohort points to a need for further confirmation in
larger prospective studies in order to determine if the
observed aberrant marker genes may be useful predictive
biomarkers.
Conclusion
We observed significant up-regulation of ERK1, ERK2,
Akt1, Akt2, PLA2G4A, prostanoid receptor EP3 and
phosphatase scaffold subunit PPP2R1B mRNA expres-
sion in normal appearing colonic mucosa of patients
with CRN. Accordingly, normal appearing mucosa of
CRN patients differs from non-CRN patients at a mo-
lecular level. Most notably, mRNA expression of
ERK1 was lifted with high significance of p = 0.007
and may therefore be considered a potential candidate
gene as predictive biomarker for developing CRN.
Our observations need to be validated in larger pro-
spective studies.
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